234 Distinct efficacy and immunological responses to αPD-1, αPD-L1 and αPD-L2 immunotherapy in aged versus young hosts

Registros relacionados

• 234 Distinct efficacy and immunological responses to αPD-1, αPD-L1 and αPD-L2 immunotherapy in aged versus young hosts
  por: Tyler Curiel, et al.
  Publicado em: (2021-11-01)
• 242 Pharmacologic tumor PD-L1 depletion with chlorambucil treats ovarian cancer and melanomas in a tumor PD-L1-dependent manner and renders αPD-L1-resistant tumors αPD-L1-sensitive
  por: Tyler Curiel, et al.
  Publicado em: (2021-11-01)
• CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation
  por: Yilun Deng, et al.
  Publicado em: (2021-04-01)
• 719 CD122-directed interleukin-2 complexes and αPD-L1 differentially require innate and adaptive immunity to treat local and metastatic bladder cancer
  por: Tyler Curiel, et al.
  Publicado em: (2020-11-01)
• 786 Distinct efficacy and immunological responses to aPD-1, aPD-L1 and aPD-L2 immunotherapy in B16 melanoma in aged versus young hosts includes T-cell stem cell effects and PD-L2 expression differences
  por: Alvaro Padron
  Publicado em: (2020-11-01)